|
ATCC
human osteosarcoma cell lines 143b ![]() Human Osteosarcoma Cell Lines 143b, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+osteosarcoma+line/143B/pmc13744650-175-0-14 Average 97 stars, based on 1 article reviews
human osteosarcoma cell lines 143b - by Bioz Stars,
2026-11
97/100 stars
|
Buy from Supplier |
|
ATCC
human osteosarcoma cell line 143b ![]() Human Osteosarcoma Cell Line 143b, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+osteosarcoma+line/143B/pmc13756348-51-0-15 Average 97 stars, based on 1 article reviews
human osteosarcoma cell line 143b - by Bioz Stars,
2026-11
97/100 stars
|
Buy from Supplier |
|
ATCC
human osteoblast like osteosarcoma cell line ![]() Human Osteoblast Like Osteosarcoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+osteosarcoma+line/MG-63/10__3390_slash_life16101733-74-0-7 Average 98 stars, based on 1 article reviews
human osteoblast like osteosarcoma cell line - by Bioz Stars,
2026-11
98/100 stars
|
Buy from Supplier |
|
ATCC
u2os human osteosarcoma cell lines ![]() U2os Human Osteosarcoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+osteosarcoma+line/U-2+OS/pmc13669654-131-2-11 Average 99 stars, based on 1 article reviews
u2os human osteosarcoma cell lines - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
ATCC
human osteosarcoma thymidine kinase deficient cell line 143b ![]() Human Osteosarcoma Thymidine Kinase Deficient Cell Line 143b, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+osteosarcoma+line/143B/bio_rxiv__64898__2026__10__11__758340-271-1-10 Average 97 stars, based on 1 article reviews
human osteosarcoma thymidine kinase deficient cell line 143b - by Bioz Stars,
2026-11
97/100 stars
|
Buy from Supplier |
|
ATCC
human osteosarcoma cell lines saos 2 ![]() Human Osteosarcoma Cell Lines Saos 2, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+osteosarcoma+line/Saos-2/pm42826871-63-1-18 Average 98 stars, based on 1 article reviews
human osteosarcoma cell lines saos 2 - by Bioz Stars,
2026-11
98/100 stars
|
Buy from Supplier |
|
ATCC
human osteosarcoma cell line ![]() Human Osteosarcoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+osteosarcoma+line/MG-63/10__2147_slash_ijn__s627313-80-2-9 Average 98 stars, based on 1 article reviews
human osteosarcoma cell line - by Bioz Stars,
2026-11
98/100 stars
|
Buy from Supplier |
|
ATCC
u2os human osteosarcoma cell line ![]() U2os Human Osteosarcoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+osteosarcoma+line/U-2+OS/10__1038_slash_s41467___026___77989___w-300-10-15 Average 99 stars, based on 1 article reviews
u2os human osteosarcoma cell line - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
ATCC
culture human osteosarcoma cell lines ![]() Culture Human Osteosarcoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+osteosarcoma+line/MG-63/10__1007_slash_s13402___026___01277___4-79-3-23 Average 98 stars, based on 1 article reviews
culture human osteosarcoma cell lines - by Bioz Stars,
2026-11
98/100 stars
|
Buy from Supplier |
Journal: MedComm
Article Title: Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids
doi: 10.1002/mco2.71134
Figure Lengend Snippet: Generation of organoids from sarcoma xenografts. (A) Representative images of organoids formed from tumor xenografts derived out of the indicated cell lines. (B) Organoids derived from the xenografts generated by parental (Par) and doxorubicin‐resistant (DXR) versions of the 143B osteosarcoma cell line. Representative images of the cultures at Days 1, 2, and 5 are shown. (C) Histological analyses (hematoxylin and eosin staining) of xenograft and organoid samples of the indicated models. Aberrant mitoses (red arrowheads) and cells with osteoid‐like material in the cytoplasm (blue arrowheads) are indicated. Scale bars: 100 µm in (A) and (B), 50 µm in (C, left panels) and 30 µm in (C, right panels). (D and E) WES analysis of DNA samples ( n = 1) from cell line (CL) and organoid (O) cultures of 143B‐Par and 143B‐DXR models. (D) UpSet plot showing the intersections of genomic variants detected by WES in 143B‐Par and 143B‐DXR cell lines (CL) and their corresponding organoid (O) models. The inset shows a correlation plot with Jaccard indices for variant overlap between models. (E) Heatmap showing the VAFs of selected cancer‐related variants across all models.
Article Snippet:
Techniques: Organoids, Derivative Assay, Generated, H&E Stain, Xenograft Assay, Analysis, Variant Assay
Journal: MedComm
Article Title: Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids
doi: 10.1002/mco2.71134
Figure Lengend Snippet: Response of parental and doxorubicin‐resistant organoids to antitumor drugs. Cell viability (CellTiter‐Glo 3D assays) measured after treatment of 143B‐Par (blue) and 143B‐DXR (red) organoids (solid line) and monolayer cultures (dotted line) with increasing concentrations of doxorubicin (DOX) (A), cisplatin (CIS) (B), methotrexate (MTX) (C), and mithramycin (MTM) (D) for 72 h. IC50 values (µM) obtained for each condition are shown. Error bars represent standard deviation of three independent biological replicates.
Article Snippet:
Techniques: Organoids, Standard Deviation
Journal: MedComm
Article Title: Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids
doi: 10.1002/mco2.71134
Figure Lengend Snippet: Transcriptomic characterization of the resistant phenotype in 143B‐DXR organoids. (A) Principal component analysis (PCA) of samples from three biological replicates of 143B‐Par (Par) and 143B‐DXR (DXR) organoids according to the top 500 most variable genes between conditions. (B) Volcano plot representing genes significantly upregulated (red) and downregulated (blue). A gene is considered differentially expressed if it has an FDR < 0.05 and a |log2FC| ≥ 1. The 10 most upregulated and downregulated genes are indicated. (C) Network representation of the statistical significance of the aggregate observed transcriptomic modulation of the gene and its interactors after applying LEAN. Only central nodes whose sub‐networks are composed of 50 nodes or more are represented. A scheme of the network including all significant nodes is shown in Figure . The color of the node indicates the log2FC from the differential expression analysis, while the color of the node border indicates corrected p value of the aggregate transcriptomic modulation according to LEAN. An unsupervised clustering of this network was performed, and the overrepresented pathway in each group is represented by the node shape. (D) Bar plot showing the top 20 hub nodes whose local networks contain a higher number of significant nodes according to LEAN. The bar color indicates the significance level for that node according to LEAN. (E) Representation of the local network centered on SRC, where node color indicates the log2FC and the border color represents the FDR from the differential expression analysis. Only the 50 most significant nodes are represented. A scheme of the SRC sub‐network including all significant nodes is shown in Figure .
Article Snippet:
Techniques: Organoids, Analysis, Quantitative Proteomics, Significance Assay
Journal: MedComm
Article Title: Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids
doi: 10.1002/mco2.71134
Figure Lengend Snippet: SRC inhibition improves the response to doxorubicin in 143B‐DXR organoids through the suppression of cJUN–mediated ABCB1 expression. (A and B) Cell viability (CellTiterGlo‐3D assays) measured after treatment of 143B‐Par and/or 143B‐DXR organoids with DMSO (control) and the indicated concentrations of doxorubicin (DOX) alone or in combination with SRC inhibitors dasatinib (Dasa) (A) or saracatinib (Sara) (B) for 72 h. (C) Western blotting analyses of the indicated proteins in control conditions or after the treatment of 143B‐Par and 143B‐DXR organoids with 1 µM doxorubicin, 1 µM dasatinib, or the combination of both for 24 h. (D) Cell viability measured after treatment of 143B‐DXR organoids with DMSO (control) and the indicated concentrations of doxorubicin (DOX) alone or in combination with the JNK–IN‐8 for 72 h. (E) Western blotting analyses of the indicated proteins in control conditions or after the treatment of 143B‐DXR organoids with 1 µM Doxorubicin, 20 µM JNK–IN‐8, or the combination of both for 24 h. Error bars in panels A, B, and D represent standard deviation of three independent biological replicates and asterisks indicate statistically significant differences between doxorubicin monotherapy and combination treatments based on one‐way ANOVA tests. *: p < 0.05; **: p < 0.01; ***: p < 0.001. Other significant differences between the treatments shown in panels A, B, and D are depicted in Figure . Quantification of Western blotting analyses ( n = 1) are shown in Figures and .
Article Snippet:
Techniques: Inhibition, Organoids, Expressing, Control, Western Blot, Standard Deviation
Journal: MedComm
Article Title: Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids
doi: 10.1002/mco2.71134
Figure Lengend Snippet: In vivo antitumor effect of the doxorubicin–dasatinib combination. Xenografted mice generated from 143B‐DXR organoids were randomly assigned to the indicated treatment groups ( n = 7). (A) Curves representing the mean relative tumor volume of xenografts during treatment. Drug efficacy, expressed as the percentage of tumor growth inhibition (TGI), is indicated. (B) Changes in body weight during treatment. (C–F) Histological analysis of tumors collected at the end of treatment. (C) Representative images of hematoxylin and eosin (H&E) staining (top panels) and immunostaining for cJUN (middle panels) and ABCB1 (bottom panels). Necrotic areas (N) are indicated. Scale bars: 100 µm for H&E and 50 µm for cJUN and ABCB1. (D) Mean necrotic score. (E) Quantification of the percentage of cells showing different levels of cJUN staining intensity. (F) Mean ABCB1 score. Error bars represent SEM in panels A and B and SD in panels D–F. In panels A and B, data are from all mice ( n = 7 per group); in panel D, from tumors of all mice reaching the experimental endpoint ( n = 6 for control and dasatinib groups; n = 7 for doxorubicin and combination groups); and in panels E and F, from four randomly selected tumors per group. Asterisks indicate statistically significant differences between groups (* p < 0.05; ** p < 0.01). In panel E, the asterisk indicates significance for the high‐intensity group. Statistical analyses were performed using one‐way ANOVA followed by Tukey's multiple‐comparison test (D and F) or two‐way ANOVA followed by Tukey's multiple‐comparison test (A and E).
Article Snippet:
Techniques: In Vivo, Generated, Organoids, Inhibition, Analysis, Staining, Immunostaining, Control, Comparison
Journal: International Journal of Genomics
Article Title: Integrative Single‐Cell and Bulk Transcriptomics Identifies a Proliferative Malignant State and Supports a Functional Contribution of TROAP in Osteosarcoma
doi: 10.1155/ijog/1407947
Figure Lengend Snippet: Integrated single‐cell landscape of human osteosarcoma. (A) Harmony‐integrated UMAP of 39,063 quality‐controlled cells colored by global cluster. (B) The same embedding colored by patient, showing cross‐patient mixing after integration. (C) Reviewed major‐cell‐type annotations displayed on the integrated UMAP; labels mark lineage centroids. (D) Relative abundance of major cell types in each patient. Colors are consistent between panels C and D.
Article Snippet: HOS and
Techniques: Single Cell
Journal: International Journal of Genomics
Article Title: Integrative Single‐Cell and Bulk Transcriptomics Identifies a Proliferative Malignant State and Supports a Functional Contribution of TROAP in Osteosarcoma
doi: 10.1155/ijog/1407947
Figure Lengend Snippet: TROAP depletion reduces clonogenic growth, overall wound closure, migration, and invasion in osteosarcoma cells. (A) Immunoblot analysis of TROAP in HOS and U2OS cells transfected with siNC, siTROAP‐1, or siTROAP‐2; beta‐actin is the loading control. (B) Colony‐formation images and colony counts. (C) Scratch‐wound images at 0 and 24 h and overall wound closure. Because the assay was not proliferation‐matched, it is not interpreted as direct migration evidence. (D) Transwell migration and invasion images and cell counts. Data are mean + /−standard deviation from three independent biological experiments. One‐way ANOVA with Dunnett′s test compared each siTROAP group with siNC; ∗∗∗ p < 0.001.
Article Snippet: HOS and
Techniques: Migration, Western Blot, Analysis, Transfection, Control, Colony Assay, Standard Deviation
Journal: bioRxiv
Article Title: Single-cell variant landscape of the human mitochondrial genome reveals cell type-specific functions and disease mechanisms
doi: 10.64898/2026.10.11.758340
Figure Lengend Snippet: (a) Overview of the study including the development and validation of scMOCHA framework and large-scale discovery workflow for single-cell mtDNA variant analysis in human PBMC and BM samples. (b) Venn diagrams summarize the homoplasmic (purple), heteroplasmic (blue), and somatic (red) variants identified across PBMC and BM datasets. (c) Circos plots illustrate the genomic distribution and allele frequency (AF) of mtDNA variants across the mitochondrial genome in PBMC and BM. Tracks from outer to inner rings are: mitochondrial genome position (black), PhastCons100way conservation (yellow), population AF derived from gnomAD (black), sample frequency of homoplasmic variants (purple) and heteroplasmic variants (blue), the mitochondrial gene annotation map (middle), mean pseudobulk AF of homoplasmic variants (purple), heteroplasmic variants (blue), and somatic variants (red).
Article Snippet: The
Techniques: Biomarker Discovery, Single Cell, Variant Assay, Analysis, Derivative Assay